Neurology IND And Fabry Agreements Will Transform Treatment

AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Published
01 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$4.10
88.2% undervalued intrinsic discount
08 Aug
US$0.48
Loading
1Y
-47.3%
7D
-10.1%

Author's Valuation

US$4.1

88.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 20%

Shared on24 Apr 25
Fair value Decreased 3.58%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 80.4x to 94.6x.

Shared on09 Apr 25
Fair value Increased 30%

AnalystConsensusTarget has decreased revenue growth from 44.4% to 23.0%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 71.3x to 80.4x and decreased shares outstanding growth rate from 0.1% to 0.1%.